ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO445

Deciphering the Chronology of Cystogenesis and Metabolic Reprogramming

Session Information

Category: Genetic Diseases of the Kidneys

  • 1201 Genetic Diseases of the Kidneys: Cystic

Authors

  • Spies, Daniel, Universita Vita Salute San Raffaele, Milano, Lombardia, Italy
  • Clerici, Sara, Universita Vita Salute San Raffaele, Milano, Lombardia, Italy
  • Cassina, Laura, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Chiaravalli, Marco, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Boletta, Alessandra, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy

Group or Team Name

  • Unit of Cystic Kidneys Disorders - Alessandra Boletta Lab.
Background

ADPKD is among the most prevalent monogenic diseases. Multiple relevant orthologous animal models were generated over the years and helped defining mechanism of disease progression and identifying therapies able to retard end-stage-kidney-disease. However, the initial stages of renal cystogenesis have been poorly defined. Identification of the cellular alterations occurring at the onset of cystogenesis would provide important information on mechanism of disease and possibly help designing better therapies targeting initiating events and being more effective.

Methods

Mutant kidneys have been characterized by IHC and IF analysis. Single cell dissociation was performed pairing mechanical and enzymatic approaches. PARSE single cell combinatorial barcoding RNA sequencing was performed on 10k cells from P54 control kidneys, with a depth of 50k reads/cell

Results

We have developed a tamoxifen-inducible Pkd1 animal model (TmKspCrePkd1fl/fl) carrying a fluorescent switch cassette (mT/mG) that allows identification of cells in which the Cre recombinase has been activated to study the initiating events in cystogenesis. Induction by 3 low dose injections of Tamoxifen resulted in full penetrance (cyst formation) within two weeks. 5 days after the last injection we identified renal tubules completely green, but not cystic, while 8 days post injection green cells started to form cysts. A pilot scRNA-seq of WT cells confirmed the capability to capture and distinguish induced from non-induced cells as well as the higher sequencing depth and reduced contamination of the combinatorial scRNA-seq approach.

Conclusion

Our inducible Pkd1 KO model enables the determination and characterization of both pre-cystic and cystic time windows, as well as the selection of low abundant pre-cystic mutant cells due to our colorSwitch reporter cassette. Comparison of mutant cells involved in cyst initiation and expansion will permit the exact determination of new mechanisms as well as therapeutic windows that allow tailoring of treatments to the corresponding metabolic stage of each cell-type. The experimental analysis is ongoing.